Skip to main content
. Author manuscript; available in PMC: 2020 Sep 1.
Published in final edited form as: Urology. 2019 May 28;131:112–119. doi: 10.1016/j.urology.2019.04.036

Table 1:

Characteristics of Low Risk Non-Muscle-Invasive Bladder Cancer Patients Undergoing Recommended vs. Overuse of Surveillance

Recommended Surveillance
(n = 283)
Overuse of Surveillance
(n = 852)
p-value
Patient Factors
Age (years), mean (SD) 76 (7) 76 (6) 0.816*
Male Sex**, n (%) >272 (99) 841 (99) 1.000Λ
Race, n (%) 0.078Λ
 White >228 (82) >727 (85)
 African-American 18 (6) 60 (7)
 Asian** <11 (1) <11 (1)
 Hispanic** <11 (1) 12 (1)
 Native American** <11 (1) <11 (1)
 Unlisted 26 (9) 39 (5)
Year of Diagnosis, n (%) 0.005
 2005 15 (5) 93 (11)
 2006 20 (7) 102 (12)
 2007 36 (13) 109 (13)
 2008 45 (16) 131 (15)
 2009 49 (17) 138 (16)
 2010 66 (23) 136 (16)
 2011 52 (18) 143 (17)
Number of Comorbidities§, n (%) 0.081
 0 49 (17) 124 (15)
 1 57 (20) 208 (24)
 2 59 (21) 217 (25)
 3 or more 118 (42) 303 (36)
Household Income ($), 44,750 45,927 0.454
 median (IQR) (38,333–63,050) (36,704–60,235)
Patient Rurality, n (%) 0.827
 Urban 158 (56) 482 (57)
 Rural 125 (44) 370 (43)
Distance to Facility (miles), 28 (11–58) 29 (11–63) 0.643
 median (IQR)
Provider Factors
Provider Age (years), mean (SD) 0.477
 <40 38 (13) 100 (12)
 ≥40 and <50 43 (15) 116 (14)
 ≥50 and <60 53 (19) 173 (20)
 ≥60 91 (32) 250 (29)
 Unlisted 58 (20) 213 (25)
Provider Sex, n (%) 0.066
 Male 217 (77) 604 (71)
 Female 23 (8) 64 (8)
 Unlisted 43 (15) 184 (22)
Facility Factors
Facility Size||, median (IQR) 150 (106–218) 150 (93–199) 0.157
Number of Urologists, mean (SD) 2 (1) 2 (1) 0.821*
Facility Rurality, n (%) 0.989
 Urban 264 (93) 795 (93)
 Rural 19 (7) 57 (7)
Complexity Level#, n (%) 0.251
 1a [most complex] 131 (46) 365 (43)
 1b 44 (16) 110 (13)
 1c 28 (10) 124 (15)
 2 68 (24) 211 (25)
 3 [least complex] 12 (4) 42 (5)

Abbreviation: SD, Standard Deviation | IQR, Interquartile Range

Percentages may not add to 100 due to rounding.

*:

Two-Sample t-Test

^:

Fisher’s Exact Test

†:

Chi-Square Test

‡:

Wilcoxon Rank Sum Test

§:

Number of Comorbidities measured by the Elixhauser Comorbidity Index

‖:

Facility Size measured by number of operating beds in fiscal year 2008

¶:

Number of Urologists measured by full-time equivalents in fiscal year 2010

#:

Complexity level as defined by the VA National Surgery Office. The complexity level reflects the complexity of surgical procedures that can be performed at each facility.

**:

Exact numbers <11 not reported to protect patient confidentiality